Abstract
The biological roles of microRNAs (miRNAs) have been extensively studied. miRNA122 represents more than half of the miRNAs expressed in the liver and has various physiological and pathological functions, which include enhancing hepatitis virus replication, regulating lipid metabolism and suppressing hepatocellular carcinoma. miRNAs, whether globally or individually, have been linked with hepatocarcinogenesis. Furthermore, some miRNAs have been shown to be involved in the pathogenesis of nonalcoholic steatohepatitis. Using nucleotide-based strategies, these miRNAs may be developed as potential therapeutic targets. Because changes in miRNA expression can be measured in sera, they may be used as non-invasive biomarkers if they correctly reflect the pathological state of the liver. In this review, we show the biological roles of representative miRNAs in liver disease and discuss the current issues that remain to be clarified for future clinical applications.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Carrington, J. & Ambros, V. Role of microRNAs in plant and animal development. Science 301, 336–338 (2003).
Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 (1993).
Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855–862 (1993).
Kozomara, A. & Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39, D152–D157 (2011).
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C. & Marks, D. S. Human MicroRNA targets. PLoS Biol. 2, e363 (2004).
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J. et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495–500 (2005).
Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005).
Ambros, V. The functions of animal microRNAs. Nature 431, 350–355 (2004).
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q. et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232–243 (2011).
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577–1581 (2005).
Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694 (2013).
Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W. J. & Pandolfi, P. P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033–1038 (2010).
Luna, J. M., Scheel, T. K., Danino, T., Shaw, K. S., Mele, A., Fak, J. J. et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 160, 1099–1110 (2015).
Tsai, W. C., Hsu, S. D., Hsu, C. S., Lai, T. C., Chen, S. J., Shen, R. et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884–2897 (2012).
Hsu, S. H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 2871–2883 (2012).
Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899 (2008).
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198–201 (2010).
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87–98 (2006).
Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K., Tuschl, T., Manoharan, M. et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438, 685–689 (2005).
Lewis, A. P. & Jopling, C. L. Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 38, 1553–1557 (2010).
Kojima, K., Takata, A., Vadnais, C., Otsuka, M., Yoshikawa, T., Akanuma, M. et al. MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat. Commun. 2, 338 (2011).
Kishikawa, T., Otsuka, M., Ohno, M., Yoshikawa, T., Takata, A. & Koike, K. Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J. Gastroenterol. 21, 8527–8540 (2015).
Xu, H., He, J., Xiao, Z., Zhang, Q., Chen, Y., Zhou, H. et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52, 1431–1442 (2010).
Laudadio, I., Manfroid, I., Achouri, Y., Schmidt, D., Wilson, M. D., Cordi, S. et al. A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology 142, 119–129 (2012).
Wang, X. W., Heegaard, N. H. & Orum, H. MicroRNAs in liver disease. Gastroenterology 142, 1431–1443 (2012).
Gatfield, D., Le Martelot, G., Vejnar, C., Gerlach, D., Schaad, O., Fleury-Olela, F. et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 23, 1313–1326 (2009).
Castoldi, M., Vujic Spasic, M., Altamura, S., Elmén, J., Lindow, M., Kiss, J. et al. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J. Clin. Invest. 121, 1386–1396 (2011).
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415–419 (2003).
Han, J., Lee, Y., Yeom, K. H., Kim, Y. K., Jin, H. & Kim, V. N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016–3027 (2004).
Denli, A. M., Tops, B. B., Plasterk, R. H., Ketting, R. F. & Hannon, G. J. Processing of primary microRNAs by the Microprocessor complex. Nature 432, 231–235 (2004).
Yi, R., Qin, Y., Macara, I. G. & Cullen, B. R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011–3016 (2003).
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E. & Kutay, U. Nuclear export of microRNA precursors. Science 303, 95–98 (2004).
Maniataki, E. & Mourelatos, Z. A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. Genes Dev. 19, 2979–2990 (2005).
Mourelatos, Z., Dostie, J., Paushkin, S., Sharma, A., Charroux, B., Abel, L. et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 16, 720–728 (2002).
Gregory, R. I., Chendrimada, T. P., Cooch, N. & Shiekhattar, R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631–640 (2005).
Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
Sekine, S., Ogawa, R., Ito, R., Hiraoka, N., McManus, M. T., Kanai, Y. et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 136, 2304–2315. e1–e4. (2009).
Kitagawa, N., Ojima, H., Shirakihara, T., Shimizu, H., Kokubu, A., Urushidate, T. et al. Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci. 104, 543–551 (2013).
Otsuka, M., Kishikawa, T., Yoshikawa, T., Ohno, M., Takata, A., Shibata, C. et al. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J. Gastroenterol. 49, 173–184 (2014).
Wu, Q., Liu, H. O., Liu, Y. D., Liu, W. S., Pan, D., Zhang, W. J. et al. Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/MicroRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J. Biol. Chem. 290, 1170–1185 (2015).
Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S. et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361, 1437–1447 (2009).
Kota, J., Chivukula, R. R., O’Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005–1017 (2009).
Viswanathan, S. R., Daley, G. Q. & Gregory, R. I. Selective blockade of microRNA processing by Lin28. Science 320, 97–100 (2008).
Clevers, H. At the crossroads of inflammation and cancer. Cell 118, 671–674 (2004).
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
Iliopoulos, D., Hirsch, H. A. & Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693–706 (2009).
He, G. et al. Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling. Cell 155, 384–396 (2013).
Zarfeshani, A., Ngo, S. & Sheppard, A. M. MicroRNA Expression Relating to Dietary-Induced Liver Steatosis and NASH. J. Clin. Med. 4, 1938–1950 (2015).
Szabo, G. & Csak, T. Role of MicroRNAs in NAFLD/NASH. Dig. Dis. Sci. 61, 1314–1324 (2016).
Loyer, X., Paradis, V., Hénique, C., Vion, A. C., Colnot, N., Guerin, C. L. et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut. doi:10.1136/gutjnl-2014-308883 (2015).
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M. et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649–653 (2011).
Ohno, M., Shibata, C., Kishikawa, T., Yoshikawa, T., Takata, A., Kojima, K. et al. The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice. Sci. Rep. 3, 2553 (2013).
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008).
Zhang, Y. C., Xu, Z., Zhang, T. F. & Wang, Y. L. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J. Gastroenterol. 21, 9853–9862 (2015).
Lin, X. J., Chong, Y., Guo, Z. W., Xie, C., Yang, X. J., Zhang, Q. et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 16, 804–815 (2015).
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 64, 800–812 (2015).
Shibata, C., Otsuka, M., Kishikawa, T., Yoshikawa, T., Ohno, M., Takata, A. et al. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol. Cell. Ther. 1, 5 (2013).
Xu, Y., Liu, L., Liu, J., Zhang, Y., Zhu, J., Chen, J. et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int. J. Cancer 128, 412–417 (2011).
Fang, Y., Xue, J. L., Shen, Q., Chen, J. & Tian, L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 55, 1852–1862 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Otsuka, M., Kishikawa, T., Yoshikawa, T. et al. MicroRNAs and liver disease. J Hum Genet 62, 75–80 (2017). https://doi.org/10.1038/jhg.2016.53
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2016.53
This article is cited by
-
Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: a case–control study
The Egyptian Journal of Internal Medicine (2025)
-
Human umbilical vein endothelial cell miRNA secretome highlights endothelial origin of serum miRNAs
Scientific Reports (2025)
-
MiRNA/mRNA network topology in hepatitis virus B-related liver cirrhosis reveals miR-20a-5p/340-5p as hubs initiating fibrosis
BMC Medical Genomics (2022)
-
Plasma circulating microRNAs associated with obesity, body fat distribution, and fat mass: the Rotterdam Study
International Journal of Obesity (2022)
-
microRNA profiles of serum exosomes derived from children with nonalcoholic fatty liver
Genes & Genomics (2022)
